DaVita price target raised to $218 from $194 at Barclays
Barclays raised the firm's price target on DaVita to $218 from $194 and keeps an Equal Weight rating on the shares. The firm adjusted targets among its U.S. healthcare facilities and managed care coverage ahead of Q2 earnings from the group.
Barclays raised the firm's price target on DaVita to $218 from $194 and keeps an Equal Weight rating on the shares.
The firm adjusted targets among its U.S. healthcare facilities and managed care coverage ahead of Q2 earnings from the group.